$17.33
5.16% yesterday
Nasdaq, Nov 25, 10:02 pm CET
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

MediWound Ltd. Stock price

$17.33
-0.15 0.86% 1M
+0.94 5.74% 6M
+7.16 70.40% YTD
+8.77 102.45% 1Y
-1.92 9.97% 3Y
-3.60 17.20% 5Y
-21.10 54.91% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.85 5.16%
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

Key metrics

Market capitalization $186.93m
Enterprise Value $165.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.22
P/S ratio (TTM) P/S ratio 9.28
P/B ratio (TTM) P/B ratio 9.01
Revenue growth (TTM) Revenue growth -22.51%
Revenue (TTM) Revenue $20.14m
EBIT (operating result TTM) EBIT $-15.35m
Free Cash Flow (TTM) Free Cash Flow $-19.90m
Cash position $29.22m
EPS (TTM) EPS $-2.16
P/E forward negative
P/S forward 7.84
EV/Sales forward 6.95
Short interest 6.43%
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

Buy
100%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
20 20
-
100%
- Direct Costs 17 17
-
87%
2.67 2.67
-
13%
- Selling and Administrative Expenses 9.90 9.90
-
49%
- Research and Development Expense 6.71 6.71
-
33%
-14 -14
-
-69%
- Depreciation and Amortization 1.41 1.41
-
7%
EBIT (Operating Income) EBIT -15 -15
-
-76%
Net Profit -20 -20
-
-99%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
GlobeNewsWire
32 minutes ago
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cas h Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, Nove...
Positive
Seeking Alpha
28 days ago
MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling...
Neutral
GlobeNewsWire
about 2 months ago
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 100
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today